Loor F - Search Results

1

FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro.

Pourtier-Manzanedo A, Boesch D, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Anticancer Drugs. 1991 Jun;2(3):279-83. doi: 10.1097/00001813-199106000-00010. Anticancer Drugs. 1991. PMID: 1724925

2

Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives.

Jachez B, Boesch D, Grassberger MA, Loor F. Jachez B, et al. Among authors: loor f. Anticancer Drugs. 1993 Apr;4(2):223-9. doi: 10.1097/00001813-199304000-00015. Anticancer Drugs. 1993. PMID: 7683935

3

Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.

Boesch D, Loor F. Boesch D, et al. Among authors: loor f. Anticancer Drugs. 1994 Apr;5(2):229-38. doi: 10.1097/00001813-199404000-00015. Anticancer Drugs. 1994. PMID: 7914109

4

SDZ 280-125: a cyclopeptolide endowed with an in vitro cyclosporin A-like profile of activity for the reversion of the P-glycoprotein-mediated multidrug resistance of tumor cells.

Jachez B, Boesch D, Emmer G, Loor F. Jachez B, et al. Among authors: loor f. Anticancer Drugs. 1994 Jun;5(3):313-20. Anticancer Drugs. 1994. PMID: 7919456

5

SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.

Pourtier-Manzanedo A, Didier AD, Muller CD, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Anticancer Drugs. 1992 Aug;3(4):419-25. doi: 10.1097/00001813-199208000-00017. Anticancer Drugs. 1992. PMID: 1421439

6

Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice.

Pourtier-Manzanedo A, Didier A, Froidevaux S, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Toxicology. 1995 May 23;99(3):207-17. doi: 10.1016/0300-483x(95)03056-l. Toxicology. 1995. PMID: 7610467

7

SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.

Loor F, Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Emmer G. Loor F, et al. Br J Cancer. 1992 Jan;65(1):11-8. doi: 10.1038/bjc.1992.3. Br J Cancer. 1992. PMID: 1346365 Free PMC article.

8

Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin A-responding mouse spleen cells by P-glycoprotein blockers.

Pourtier-Manzanedo A, Didier A, Loor F. Pourtier-Manzanedo A, et al. Among authors: loor f. Oncol Res. 1992;4(11-12):473-80. Oncol Res. 1992. PMID: 1363723

9

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833.

Boesch D, Gavériaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. Boesch D, et al. Among authors: loor f. Cancer Res. 1991 Aug 15;51(16):4226-33. Cancer Res. 1991. PMID: 1678313

10

Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.

Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Boesch D, et al. Among authors: loor f. Exp Cell Res. 1991 Sep;196(1):26-32. doi: 10.1016/0014-4827(91)90452-z. Exp Cell Res. 1991. PMID: 1879470

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters